{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:49:31Z","timestamp":1790304571877,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1097\/fpc.0000000000000319","type":"journal-article","created":{"date-parts":[[2017,11,25]],"date-time":"2017-11-25T20:41:22Z","timestamp":1511642482000},"page":"56-67","source":"Crossref","is-referenced-by-count":38,"title":["Cost-effectiveness analysis of HLA-B*58"],"prefix":"10.1097","volume":"28","author":[{"given":"Huey Yi","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Heng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthamas","family":"Prawjaeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichittra","family":"Tassaneeyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahurin","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210213","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R2-4-20210213","first-page":"925","article-title":"Gout and hyperuricemia","volume":"59","author":"Harris","year":"1999","journal-title":"Am Fam Physician"},{"key":"R3-4-20210213","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R4-4-20210213","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00002281-200105000-00016","article-title":"Gout: can management be improved?","volume":"13","author":"Schlesinger","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"R5-4-20210213","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R6-4-20210213","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1136\/bmj.290.6486.1969","article-title":"Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis","volume":"290","author":"Aubock","year":"1985","journal-title":"Br Med J (Clin Res Ed"},{"key":"R7-4-20210213","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R8-4-20210213","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R9-4-20210213","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"R10-4-20210213","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"R11-4-20210213","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R12-4-20210213","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B 5801 and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R13-4-20210213","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R14-4-20210213","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R15-4-20210213","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R16-4-20210213","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B 58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R17-4-20210213","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B 58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"R18-4-20210213","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B 58:01 is a risk factor for allopurinol-induced DRESS and Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Goncalo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R19-4-20210213","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R20-4-20210213","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B 5801 allele and allopurinol-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"R22-4-20210213","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R24-4-20210213","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R25-4-20210213","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for Management of Gout. Part I: systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R26-4-20210213","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R28-4-20210213","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R29-4-20210213","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R30-4-20210213","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2217\/pgs.15.125","article-title":"Cost-effectiveness analysis of genotyping for HLA-B 5801 and an enhanced safety program in gout patients starting allopurinol in Singapore","volume":"16","author":"Dong","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R31-4-20210213","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R32-4-20210213","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R33-4-20210213","first-page":"Cd006077","article-title":"Allopurinol for chronic gout","volume":"10","author":"Seth","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R35-4-20210213","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1093\/hmg\/ddu149","article-title":"Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations","volume":"23","author":"Pillai","year":"2014","journal-title":"Hum Mol Genet"},{"key":"R36-4-20210213","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4103\/0378-6323.102367","article-title":"An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia","volume":"78","author":"Choon","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R37-4-20210213","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","article-title":"Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore","volume":"79","author":"Dong","year":"2012","journal-title":"Neurology"},{"key":"R38-4-20210213","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2340\/00015555-2295","article-title":"Long-term sequelae of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"96","author":"Yang","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R41-4-20210213","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/bjd.15498","article-title":"Is universal HLA-B*15:02 screening a cost-effective option in an ethnically-diverse population? A case study of Malaysia","volume":"177","author":"Chong","year":"2017","journal-title":"Br J Dermatol"},{"key":"R43-4-20210213","doi-asserted-by":"crossref","first-page":"e007214","DOI":"10.1136\/bmjopen-2014-007214","article-title":"Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis","volume":"5","author":"Jackson","year":"2015","journal-title":"BMJ Open"},{"key":"R44-4-20210213","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0094294","article-title":"Cost-Effectiveness analysis of HLA-B 5801 testing in preventing allopurinol-induced SJS\/TEN in Thai population","volume":"9","author":"Saokaew","year":"2014","journal-title":"PLoS One"},{"key":"R46-4-20210213","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11096-007-9185-0","article-title":"Cost of illness of tuberculosis in Penang, Malaysia","volume":"30","author":"Elamin","year":"2008","journal-title":"Pharm World Sci"},{"key":"R49-4-20210213","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1542-0124(12)70043-5","article-title":"Utility assessment to measure the impact of dry eye disease","volume":"4","author":"Buchholz","year":"2006","journal-title":"Ocul Surf"},{"key":"R50-4-20210213","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0161-6420(03)00462-7","article-title":"Utility assessment among patients with dry eye disease","volume":"110","author":"Schiffman","year":"2003","journal-title":"Ophthalmology"},{"key":"R51-4-20210213","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MLR.0b013e318234a04a","article-title":"Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods","volume":"50","author":"Ara","year":"2012","journal-title":"Med Care"},{"key":"R53-4-20210213","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-014-0617-1","article-title":"Cost-effectiveness of febuxostat in chronic gout","volume":"15","author":"Beard","year":"2014","journal-title":"Eur J Health Econ"},{"key":"R54-4-20210213","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"R55-4-20210213","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-b*5801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R56-4-20210213","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/acr.22409","article-title":"Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea","volume":"67","author":"Park","year":"2015","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R57-4-20210213","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions","volume":"44","author":"Ke","year":"2017","journal-title":"J Rheumatol"},{"key":"R58-4-20210213","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R62-4-20210213","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jcpt.12322","article-title":"Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"40","author":"Chou","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"R64-4-20210213","first-page":"251","article-title":"Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?","volume":"48","author":"Paschou","year":"2016","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"R65-4-20210213","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1556\/OH.2012.29324","article-title":"Allopurinol-induced hypersensitivity syndrome","volume":"153","author":"Kinyo","year":"2012","journal-title":"Orv Hetil"},{"key":"R66-4-20210213","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.burns.2015.03.012","article-title":"Complications of Stevens\u2013Johnson syndrome beyond the eye and skin","volume":"42","author":"Saeed","year":"2016","journal-title":"Burns"},{"key":"R67-4-20210213","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13075-016-1211-y","article-title":"Factors associated with initiation and persistence of urate-lowering therapy","volume":"19","author":"Dehlin","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R68-4-20210213","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","article-title":"Adherence with urate-lowering therapies for the treatment of gout","volume":"11","author":"Harrold","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R69-4-20210213","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FPC.0000000000000285","article-title":"Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population","volume":"27","author":"Saksit","year":"2017","journal-title":"Pharmacogenet Genomics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:24:13Z","timestamp":1620937453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201802000-00004"}},"subtitle":["01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in a Malaysian population"],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000319","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}